Thomas U. Ahearn

ORCID: 0000-0003-0771-7752
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • BRCA gene mutations in cancer
  • Genetic Associations and Epidemiology
  • Global Cancer Incidence and Screening
  • Nutrition, Genetics, and Disease
  • Cancer Genomics and Diagnostics
  • Cancer Risks and Factors
  • Prostate Cancer Treatment and Research
  • Genetic factors in colorectal cancer
  • Breast Cancer Treatment Studies
  • Cancer, Lipids, and Metabolism
  • Colorectal Cancer Screening and Detection
  • Estrogen and related hormone effects
  • Cervical Cancer and HPV Research
  • Gene expression and cancer classification
  • Bioinformatics and Genomic Networks
  • Molecular Biology Techniques and Applications
  • Genomic variations and chromosomal abnormalities
  • Genomics and Rare Diseases
  • Vitamin D Research Studies
  • Prostate Cancer Diagnosis and Treatment
  • RNA Research and Splicing
  • Nutritional Studies and Diet
  • Health, Environment, Cognitive Aging
  • Ginger and Zingiberaceae research
  • Cardiovascular Health and Risk Factors

National Institutes of Health
2018-2025

National Cancer Institute
2017-2025

Division of Cancer Epidemiology and Genetics
2018-2025

Cancer Institute (WIA)
2010-2024

Government of the United States of America
2019-2021

University of Manchester
2021

St Mary's Hospital
2021

Edinburgh Cancer Research
2021

Cancer Research Center
2021

Harvard University
2013-2020

Nasim Mavaddat Kyriaki Michailidou Joe Dennis Michael Lush Laura Fachal and 95 more Andrew Lee Jonathan P. Tyrer Ting‐Huei Chen Qin Wang Manjeet K. Bolla Xin Yang Muriel A. Adank Thomas U. Ahearn Kristiina Aittomäki Jamie Allen Irene L. Andrulis Hoda Anton‐Culver Natalia Antonenkova Volker Arndt Kristan J. Aronson Paul L. Auer Päivi Auvinen Myrto Barrdahl Laura E. Beane Freeman Matthias W. Beckmann Sabine Behrens Javier Benı́tez Marina Bermisheva Leslie Bernstein Carl Blomqvist Natalia Bogdanova Stig E. Bojesen Bernardo Bonanni Anne‐Lise Børresen‐Dale Hiltrud Brauch Michael Bremer Hermann Brenner Adam R. Brentnall Ian W. Brock Angela Brooks‐Wilson Sara Y. Brucker Thomas Brüning Barbara Burwinkel Daniele Campa Brian D. Carter Jose E. Castelao Stephen J. Chanock Rowan T. Chlebowski Hans Christiansen Christine L. Clarke J. Margriet Collée Emilie Cordina‐Duverger Sten Cornelissen Fergus J. Couch Angela Cox Simon S. Cross Kamila Czene Mary B. Daly Peter Devilee Thilo Dörk Isabel dos‐Santos‐Silva Martine Dumont Lorraine Durcan Miriam Dwek Diana Eccles Arif B. Ekici A. Heather Eliassen Carolina Ellberg Christoph Engel Mikael Eriksson D. Gareth Evans Peter A. Fasching Jonine D. Figueroa Olivia Fletcher Henrik Flyger Asta Försti Lin Fritschi Marike Gabrielson Manuela Gago‐Dominguez Susan M. Gapstur José Á. García-Sáenz Mia M. Gaudet V. Georgoulias Graham G. Giles I. R. Gilyazova Gord Glendon Mark S. Goldberg David E. Goldgar Anna González‐Neira Grethe I.G. Alnæs Mervi Grip Jacek Gronwald Anne Grundy Pascal Guénel Lothar Haeberle Eric Hahnen Christopher A. Haiman Niclas Håkansson Ute Hamann Susan E. Hankinson

Stratification of women according to their risk breast cancer based on polygenic scores (PRSs) could improve screening and prevention strategies. Our aim was develop PRSs, optimized for prediction estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset empirically validate PRSs in prospective studies. The development comprised 94,075 case subjects 75,017 control European ancestry 69 studies, divided into training validation sets. Samples were...

10.1016/j.ajhg.2018.11.002 article EN cc-by-nc-nd The American Journal of Human Genetics 2018-12-13
Leila Dorling Sara Carvalho Jamie Allen Anna González‐Neira Craig Luccarini and 95 more Cecilia Wahlström Karen A. Pooley Michael T. Parsons Cristina Fortuño Qin Wang Manjeet K. Bolla Joe Dennis Renske Keeman M. Rosario Alonso Núria Álvarez Belén Herráez María Victoria Fernández Rocío Núñez‐Torres Ana Osório Jeanette Valcich Minerva Li Therese Törngren Patricia Harrington Caroline Baynes Don Conroy Brennan Decker Laura Fachal Nasim Mavaddat Thomas U. Ahearn Kristiina Aittomäki Natalia Antonenkova Norbert Arnold Patrick Arveux Margreet G.E.M. Ausems Päivi Auvinen Heiko Becher Matthias W. Beckmann Sabine Behrens Marina Bermisheva Katarzyna Białkowska Carl Blomqvist Natalia Bogdanova Nadja Bogdanova-Markov Stig E. Bojesen Bernardo Bonanni Anne‐Lise Børresen‐Dale Hiltrud Brauch Michael Bremer Ignacio Briceño Thomas Brüning Barbara Burwinkel David Cameron Nicola J. Camp Archie Campbell Ángel Carracedo Jose E. Castelao Melissa H. Cessna Stephen J. Chanock Hans Christiansen J. Margriet Collée Emilie Cordina‐Duverger Sten Cornelissen Kamila Czene Thilo Dörk Arif B. Ekici Christoph Engel Mikael Eriksson Peter A. Fasching Jonine D. Figueroa Henrik Flyger Asta Försti Marike Gabrielson Manuela Gago‐Dominguez V. Georgoulias Fabián Gil Graham G. Giles Gord Glendon E. Gómez Grethe I.G. Alnæs Pascal Guénel Andreas Hadjisavvas Lothar Haeberle Eric Hahnen Per Hall Ute Hamann Elaine F. Harkness Jaana M. Hartikainen Mikael Hartman Wei He Bernadette A. M. Heemskerk‐Gerritsen Peter Hillemanns Frans B.L. Hogervorst Antoinette Hollestelle Weang-Kee Ho Maartje J. Hooning Anthony Howell Keith Humphreys Faiza Idris Anna Jakubowska Audrey Jung

Genetic testing for breast cancer susceptibility is widely used, but many genes, evidence of an association with weak, underlying risk estimates are imprecise, and reliable subtype-specific lacking.

10.1056/nejmoa1913948 article EN New England Journal of Medicine 2021-01-20
Katherine S. Ruth Felix R. Day Jazib Hussain Ana Martínez-Marchal Catherine Aiken and 95 more Ajuna Azad Deborah J. Thompson Lucie Knoblochová Hironori Abe Jane L. Tarry‐Adkins Javier Martín‐González Pierre Fontanillas Annique Claringbould Olivier B. Bakker Patrick Sulem Robin Walters Chikashi Terao Sandra Turon Momoko Horikoshi Kuang Lin N. Charlotte Onland‐Moret Aditya Sankar Emil Peter Thrane Hertz Pascal Timshel Vallari Shukla Rehannah Borup Kristina Wendelboe Olsen Paula Aguilera Mònica Ferrer‐Roda Yan Huang Stasa Stankovic Paul R. H. J. Timmers Thomas U. Ahearn Behrooz Z. Alizadeh Elnaz Naderi Irene L. Andrulis Alice M. Arnold Kristan J. Aronson Annelie Augustinsson Stefania Bandinelli Caterina Barbieri Robin N. Beaumont Heiko Becher Matthias W. Beckmann Stefania Benónísdóttir Sven Bergmann Murielle Bochud Eric Boerwinkle Stig E. Bojesen Manjeet K. Bolla Dorret I. Boomsma Nicholas Bowker Jennifer A. Brody Linda Broer Julie E. Buring Archie Campbell Harry Campbell Jose E. Castelao Eulalia Catamo Stephen J. Chanock Georgia Chenevix‐Trench Marina Ciullo Tanguy Corre Fergus J. Couch Angela Cox Laura Crisponi Simon S. Cross Francesco Cucca Kamila Czene George Davey Smith Eco J. C. de Geus Renée de Mutsert Immaculata De Vivo Ellen W. Demerath Joe Dennis Alison M. Dunning Miriam Dwek Mikael Eriksson Tõnu Esko Peter A. Fasching Jessica D. Faul Luigi Ferrucci Nora Franceschini Timothy M. Frayling Manuela Gago‐Dominguez Massimo Mezzavilla Montserrat García‐Closas Christian Gieger Graham G. Giles Harald Grallert Daníel F. Guðbjartsson Vilmundur Guðnason Pascal Guénel Christopher A. Haiman Niclas Håkansson Per Hall Caroline Hayward Chunyan He Wei He Gerardo Heiss

10.1038/s41586-021-03779-7 article EN Nature 2021-08-04

Background: PTEN is a tumor suppressor frequently deleted in prostate cancer that may be useful prognostic biomarker.However, the association of loss with lethal disease has not been tested large, predominantly surgically treated cohort. Methods:In Health Professionals Follow-up Study and Physicians' Study, we followed 1044 incident cases diagnosed between 1986 2009 for cancer-specific all-cause mortality.A genetically validated immunohistochemistry (IHC) assay was performed on tissue...

10.1093/jnci/djv346 article EN JNCI Journal of the National Cancer Institute 2015-02-01
Nasim Mavaddat Leila Dorling Sara Carvalho Jamie Allen Anna González‐Neira and 89 more Renske Keeman Manjeet K. Bolla Joe Dennis Qin Wang Thomas U. Ahearn Irene L. Andrulis Matthias W. Beckmann Sabine Behrens Javier Benı́tez Marina Bermisheva Carl Blomqvist Natalia Bogdanova Stig E. Bojesen Ignacio Briceño Thomas Brüning Nicola J. Camp Archie Campbell Jose E. Castelao Jenny Chang‐Claude Stephen J. Chanock Georgia Chenevix‐Trench Hans Christiansen Kamila Czene Thilo Dörk Mikael Eriksson D. Gareth Evans Peter A. Fasching Jonine D. Figueroa Henrik Flyger Marike Gabrielson Manuela Gago‐Dominguez Jürgen Geisler Graham G. Giles Pascal Guénel Andreas Hadjisavvas Eric Hahnen Per Hall Ute Hamann Jaana M. Hartikainen Mikael Hartman Reiner Hoppe Sacha J. Howell Anna Jakubowska Audrey Jung Э. К. Хуснутдинова Vessela N. Kristensen Jingmei Li Swee Ho Lim Annika Lindblom Maria A. Loizidou Artitaya Lophatananon Jan Lubiński Michael J. Madsen Graham J. Mann Mehdi Manoochehri Sara Margolin Dimitrios Mavroudis Roger L. Milne Nur Aishah Mohd Taib Anna Morra Kenneth Muir Nadia Obi Ana Osório Tjoung‐Won Park‐Simon Paolo Peterlongo Paolo Radice Emmanouil Saloustros Elinor J. Sawyer Rita K. Schmutzler Mitul Shah Xueling Sim Melissa C. Southey Heather Thorne Ian Tomlinson Diana Torres Thérèse Truong Cheng Har Yip Amanda B. Spurdle Maaike P.G. Vreeswijk Alison M. Dunning Montserrat García‐Closas Paul D.P. Pharoah Anders Kvist Taru Muranen Heli Nevanlinna Soo‐Hwang Teo Peter Devilee Marjanka K. Schmidt Douglas F. Easton

Rare germline genetic variants in several genes are associated with increased breast cancer (BC) risk, but their precise contributions to different disease subtypes unclear. This information is relevant guidelines for gene panel testing and risk prediction.To characterize tumors BC susceptibility large-scale population- or hospital-based studies.The multicenter, international case-control analysis of the BRIDGES study included 42 680 patients 46 387 control participants, comprising women...

10.1001/jamaoncol.2021.6744 article EN cc-by JAMA Oncology 2022-01-27

Vitamin D and calcium affect several pathways involved in inflammation, tumor growth, immune surveillance relevant to carcinogenesis. Also, epidemiologic evidence indicates that vitamin may reduce risk for developing colorectal adenomas cancer. To investigate the effects of on biomarkers inflammation adenoma patients, we conducted a pilot, randomized, double-blind, placebo-controlled, 2 × factorial clinical trial (n = 92) g/d and/or 800 IU/d D(3) supplementation versus placebo over 6 months....

10.1158/1940-6207.capr-11-0105 article EN Cancer Prevention Research 2011-07-01

Abstract Background External validation of risk models is critical for risk-stratified breast cancer prevention. We used the Individualized Coherent Absolute Risk Estimation (iCARE) as a flexible tool model development and comparative to make projections population stratification. Methods Performance two recently developed models, one based on Breast Prostate Cancer Cohort Consortium analysis (iCARE-BPC3) another literature review (iCARE-Lit), were compared with established (Breast...

10.1093/jnci/djz113 article EN JNCI Journal of the National Cancer Institute 2019-05-30

The gut microbiota may play a role in breast cancer etiology by regulating hormonal, metabolic and immunologic pathways. We investigated associations of fecal bacteria with nonmalignant disease case-control study conducted Ghana, country rising incidence mortality. To do this, we sequenced the V4 region 16S rRNA gene to characterize samples collected at time biopsy (N = 379 cases, N 102 414 population-based controls). estimated alpha diversity (observed amplicon sequence variants [ASVs],...

10.1002/ijc.33473 article EN International Journal of Cancer 2021-01-18
Suzanne C. Dixon‐Suen Sarah J. Lewis Richard M. Martin Dallas R. English Terry Boyle and 95 more Graham G. Giles Kyriaki Michailidou Manjeet K. Bolla Qin Wang Joe Dennis Michael Lush ABCTB Investigators Thomas U. Ahearn Christine B. Ambrosone Irene L. Andrulis Hoda Anton‐Culver Volker Arndt Kristan J. Aronson Annelie Augustinsson Päivi Auvinen Laura E. Beane Freeman Heiko Becher Matthias W. Beckmann Sabine Behrens Marina Bermisheva Carl Blomqvist Natalia Bogdanova Stig E. Bojesen Bernardo Bonanni Hermann Brenner Thomas Brüning Saundra S. Buys Nicola J. Camp Daniele Campa Federico Canzian Jose E. Castelao Melissa H. Cessna Jenny Chang‐Claude Stephen J. Chanock Christine L. Clarke Don Conroy Fergus J. Couch Angela Cox Simon S. Cross Kamila Czene Mary B. Daly Peter Devilee Thilo Dörk Miriam Dwek Diana Eccles A. Heather Eliassen Christoph Engel Mikael Eriksson D. Gareth Evans Peter A. Fasching Olivia Fletcher Henrik Flyger Lin Fritschi Marike Gabrielson Manuela Gago‐Dominguez Montserrat García‐Closas José Á. García-Sáenz Mark S. Goldberg Pascal Guénel Melanie Gündert Eric Hahnen Christopher A. Haiman Lothar Häberle Niclas Håkansson Per Hall Ute Hamann Steven N. Hart Michelle Harvie Peter Hillemanns Antoinette Hollestelle Maartje J. Hooning Reiner Hoppe John L. Hopper Anthony Howell David J. Hunter Anna Jakubowska Wolfgang Janni Esther M. John Audrey Jung Rudolf Kaaks Renske Keeman Cari M. Kitahara Stella Koutros Peter Kraft Vessela N. Kristensen Katerina Kubelka‐Sabit Allison W. Kurian James V. Lacey Diether Lambrechts Loı̈c Le Marchand Annika Lindblom Sibylle Loibl Jan Lubiński Arto Mannermaa Mehdi Manoochehri

Physical inactivity and sedentary behaviour are associated with higher breast cancer risk in observational studies, but ascribing causality is difficult. Mendelian randomisation (MR) assesses by simulating randomised trial groups using genotype. We assessed whether lifelong physical activity or time, genotype, may be causally overall, pre/post-menopause, case-groups defined tumour characteristics.

10.1136/bjsports-2021-105132 article EN British Journal of Sports Medicine 2022-09-06
Leila Dorling Sara Carvalho Jamie Allen Michael T. Parsons Cristina Fortuño and 95 more Anna González‐Neira Stephan Heijl Muriel A. Adank Thomas U. Ahearn Irene L. Andrulis Päivi Auvinen Heiko Becher Matthias W. Beckmann Sabine Behrens Marina Bermisheva Natalia Bogdanova Stig E. Bojesen Manjeet K. Bolla Michael Bremer Ignacio Briceño Nicola J. Camp Archie Campbell Jose E. Castelao Jenny Chang-Claude Stephen J. Chanock Georgia Chenevix‐Trench J. Margriet Collée Kamila Czene Joe Dennis Thilo Dörk Mikael Eriksson D. Gareth Evans Peter A. Fasching Jonine D. Figueroa Henrik L. Flyger Marike Gabrielson Manuela Gago‐Dominguez Montserrat García‐Closas Graham G. Giles Gord Glendon Pascal Guénel Melanie Gündert Andreas Hadjisavvas Eric Hahnen Per Hall Ute Hamann Elaine F. Harkness Mikael Hartman Frans B.L. Hogervorst Antoinette Hollestelle Reiner Hoppe Sacha J. Howell Anna Jakubowska Audrey Jung Elza Khusnutdinova Sung-Won Kim Yon‐Dschun Ko Vessela N. Kristensen Inge M.M. Lakeman Jingmei Li Annika Lindblom Maria A. Loizidou Artitaya Lophatananon Jan Lubiński Craig Luccarini Michael J. Madsen Arto Mannermaa Mehdi Manoochehri Sara Margolin Dimitrios Mavroudis Roger L. Milne Nur Aishah Mohd Taib Kenneth Muir Heli Nevanlinna William G. Newman Jan C. Oosterwijk Sue K. Park Paolo Peterlongo Paolo Radice Emmanouil Saloustros Elinor J. Sawyer Rita K. Schmutzler Mitul Shah Xueling Sim Melissa C. Southey Harald Surowy Maija Suvanto Ian Tomlinson Diana Torres Thérèse Truong Christi J. van Asperen Regina Waltes Qin Wang Xiaohong R. Yang Paul D.P. Pharoah Marjanka K. Schmidt Javier Benı́tez Bas Vroling Alison M. Dunning Soo‐Hwang Teo

Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 are associated with increased breast cancer risk, but risks missense these genes uncertain. We analyzed data on 59,639 cases 53,165 controls from studies participating the Breast Cancer Association Consortium BRIDGES project. sampled training (80%) validation (20%) sets to analyze rare ATM (1146 variants), BRCA1 (644), BRCA2 (1425), CHEK2 (325), (472). evaluated according five silico prediction-of-deleteriousness algorithms,...

10.1186/s13073-022-01052-8 article EN cc-by Genome Medicine 2022-05-18
Katherine A. Kentistou Lena R Kaisinger Stasa Stankovic Marc Vaudel Edson Mendes de Oliveira and 95 more Andrea Messina Robin Walters Xiaoxi Liu Alexander S Busch Hannes Helgason Deborah J Thompson Federico Santoni Konstantin M. Petricek Yassine Zouaghi Isabel Huang-Doran Daníel F. Guðbjartsson Eirik Bratland Kuang Lin Eugene J. Gardner Yajie Zhao Raina Y Jia Chikashi Terao Marjorie J Riggan Manjeet K Bolla Mojgan Yazdanpanah Nahid Yazdanpanah Jonathan P Bradfield Linda Broer Archie Campbell Daniel I. Chasman Diana L. Cousminer Nora Franceschini Lude Franke Giorgia Girotto Chunyan He Marjo‐Riitta Järvelin Peter K. Joshi Yoichiro Kamatani Robert Karlsson Jian’an Luan Kathryn L. Lunetta Reedik Mägi Massimo Mangino Sarah E. Medland Christa Meisinger Raymond Noordam Teresa Nutile Maria Pina Concas Ozren Polašek Eleonora Porcu Susan M. Ring Cinzia Sala Albert V. Smith Toshiko Tanaka Peter J. van der Most Veronique Vitart Carol A. Wang Gonneke Willemsen Marek Zygmunt Thomas U. Ahearn Irene L. Andrulis Hoda Anton-Culver Antonis C Antoniou Paul L. Auer Catriona L K Barnes Matthias W Beckmann Amy Berrington de González Natalia Bogdanova Stig E. Bojesen Hermann Brenner Julie E. Buring Federico Canzian Jenny Chang‐Claude Fergus J Couch Angela Cox Laura Crisponi Kamila Czene Mary B. Daly Ellen W. Demerath Joe Dennis Peter Devilee Immaculata De Vivo Thilo Dörk Alison M. Dunning Miriam Dwek Johan G. Eriksson Peter A. Fasching Lindsay Fernández‐Rhodes Liana Ferreli Olivia Fletcher Manuela Gago‐Dominguez Montserrat García‐Closas José A. García‐Sáenz Anna González‐Neira Harald Grallert Pascal Guénel Christopher A. Haiman Per Hall Ute Hamann Hákon Hákonarson

Abstract Pubertal timing varies considerably and is associated with later health outcomes. We performed multi-ancestry genetic analyses on ~800,000 women, identifying 1,080 signals for age at menarche. Collectively, these explained 11% of trait variance in an independent sample. Women the top bottom 1% polygenic risk exhibited ~11 ~14-fold higher risks delayed precocious puberty, respectively. identified several genes harboring rare loss-of-function variants ~200,000 including ZNF483 , which...

10.1038/s41588-024-01798-4 article EN cc-by Nature Genetics 2024-07-01

Abstract To estimate the effects of ginger on apoptosis, proliferation, and differentiation in normal-appearing colonic mucosa, we randomized 20 people at increased risk for colorectal cancer to 2.0 g or placebo daily 28 days a pilot trial. Overall expression distributions Bax, Bcl-2, p21, hTERT, MIB-1 (Ki-67) crypts rectal mucosa biopsies were measured using automated immunohistochemistry quantitative image analysis. Relative placebo, Bax group decreased 15.6% (P = 0.78) whole crypts, 6.6%...

10.1158/1940-6207.capr-12-0327 article EN Cancer Prevention Research 2013-01-10

Abstract Purpose: Breast and prostate cancer co-occur in families, women with a family history of are at increased breast risk. Prostate is among the most heritable cancers, but few studies have investigated its association familial cancer. The objective this study to investigate extent which or first-degree relatives increases Experimental Design: A prospective 37,002 U.S. men Health Professionals Follow-up Study. During 16-year follow-up 2012, 4,208 total 344 lethal cases were diagnosed....

10.1158/1078-0432.ccr-18-0370 article EN Clinical Cancer Research 2018-08-06
Pooja Middha Nasim Mavaddat Parichoy Pal Choudhury Amber N. Wilcox Sara Lindstrӧm and 95 more Sabine Behrens Kyriaki Michailidou Joe Dennis Manjeet K. Bolla Qin Wang Audrey Jung Zomoroda Abu‐Ful Thomas U. Ahearn Irene L. Andrulis Hoda Anton‐Culver Volker Arndt Kristan J. Aronson Paul L. Auer Laura E. Beane Freeman Heiko Becher Matthias W. Beckmann Alicia Beeghly‐Fadiel Javier Benı́tez Leslie Bernstein Stig E. Bojesen Hiltrud Brauch Hermann Brenner Thomas Brüning Qiuyin Cai Daniele Campa Federico Canzian Ángel Carracedo Brian D. Carter Jose E. Castelao Stephen J. Chanock Nilanjan Chatterjee Georgia Chenevix‐Trench Christine L. Clarke Fergus J. Couch Angela Cox Simon S. Cross Kamila Czene James Y. Dai H. Shelton Earp Arif B. Ekici A. Heather Eliassen Mikael Eriksson D. Gareth Evans Peter A. Fasching Jonine D. Figueroa Lin Fritschi Marike Gabrielson Manuela Gago‐Dominguez Chi Gao Susan M. Gapstur Mia M. Gaudet Graham G. Giles Anna González‐Neira Pascal Guénel Lothar Haeberle Christopher A. Haiman Niclas Håkansson Per Hall Ute Hamann Sigrid Hatse Jane Heyworth Bernd Holleczek Robert N. Hoover John L. Hopper Anthony Howell David J. Hunter Esther M. John Michael E. Jones Rudolf Kaaks Renske Keeman Cari M. Kitahara Yon-Dschun Ko Stella Koutros Allison W. Kurian Diether Lambrechts Loı̈c Le Marchand Eunjung Lee Flavio Lejbkowicz Martha S. Linet Jolanta Lissowska Ana Llaneza Robert J. MacInnis Maria Elena Martinez Tabea Maurer Catriona McLean Susan L. Neuhausen William G. Newman Aaron D. Norman Katie M. O’Brien Andrew F. Olshan Janet E. Olson Håkan Olsson Nick Orr Charles M. Perou Guillermo Pita

We evaluated the joint associations between a new 313-variant PRS (PRS313) and questionnaire-based breast cancer risk factors for women of European ancestry, using 72 284 cases 80 354 controls from Breast Cancer Association Consortium. Interactions were standard logistic regression newly developed case-only method overall by estrogen receptor status. After accounting multiple testing, we did not find evidence that per-standard deviation PRS313 odds ratio differed across strata defined...

10.1093/jnci/djaa056 article EN cc-by JNCI Journal of the National Cancer Institute 2020-04-23

Abstract Background Polygenic risk scores (PRSs) have been demonstrated to identify women of European, Asian, and Latino ancestry at elevated developing breast cancer (BC). We evaluated the performance existing PRSs trained in European populations among African ancestry. Methods assembled genotype data for ancestry, including 9241 case subjects 10 193 control subjects. associations 179- 313-variant with overall subtype-specific BC risk. PRS discriminatory accuracy was assessed using area...

10.1093/jnci/djab050 article EN JNCI Journal of the National Cancer Institute 2021-03-23

Abstract Background Reproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations intrinsic-like subtypes are less clear. Methods Analyses included up 23 353 cases 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used estimate association...

10.1093/jnci/djac117 article EN JNCI Journal of the National Cancer Institute 2022-06-20
Josephine Lopes Cardozo Irene L. Andrulis Stig E. Bojesen Thilo Dörk Diana Eccles and 95 more Peter A. Fasching Maartje J. Hooning Renske Keeman Heli Nevanlinna Emiel J. Rutgers Douglas F. Easton Per Hall Paul D.P. Pharoah Laura van ′t Veer Marjanka K. Schmidt Thomas U. Ahearn Hoda Anton‐Culver Volker Arndt Paul L. Auer Annelie Augustinsson Laura E. Beane Freeman Heiko Becher Matthias W. Beckmann Sabine Behrens Javier Benı́tez Marina Bermisheva Carl Blomqvist Manjeet K. Bolla Bernardo Bonanni Terry Boyle Hermann Brenner Sara Y. Brucker Thomas Brüning Barbara Burwinkel Saundra S. Buys Nicola J. Camp Federico Canzian Fátima Cardoso Jose E. Castelao Melissa H. Cessna Tsun Leung Chan Jenny Chang‐Claude Georgia Chenevix‐Trench Ji‐Yeob Choi Sarah V. Colonna Ellen Copson Fergus J. Couch Angela Cox Simon S. Cross Kamila Czene Mary B. Daly Joe Dennis Peter Devilee Caroline A. Drukker Alison M. Dunning Miriam Dwek A. Heather Eliassen Christoph Engel D. Gareth Evans Jonine D. Figueroa Olivia Fletcher Henrik Flyger Manuela Gago‐Dominguez Montserrat García‐Closas José A. García‐Sáenz Jeanine M. Genkinger Graham G. Giles Anna González‐Neira Pascal Guénel Melanie Gündert Eric Hahnen Christopher A. Haiman Niclas Håkansson Ute Hamann Mikael Hartman Bernadette A. M. Heemskerk‐Gerritsen Alexander Hein Weang-Kee Ho Reiner Hoppe John L. Hopper Richard S. Houlston Anthony Howell David J. Hunter Hidemi Ito Anna Jakubowska Helena Jernström Esther M. John Nichola Johnson Michael E. Jones Joseph Vijai Rudolf Kaaks Daehee Kang Sung-Won Kim Cari M. Kitahara Linetta B. Koppert Veli‐Matti Kosma Peter Kraft Vessela N. Kristensen Katerina Kubelka‐Sabit Stella Koutros

PURPOSE A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS ) is associated with breast cancer and contralateral cancer. This study aimed to evaluate the association PRS clinicopathologic characteristics of, survival following, METHODS Women invasive were included, 98,397 European ancestry 12,920 Asian ancestry, from Breast Cancer Association Consortium (BCAC), 683 women MINDACT trial. Associations between characteristics, including 70-gene signature for MINDACT,...

10.1200/jco.22.01978 article EN Journal of Clinical Oncology 2023-01-23

Abstract Data sharing is essential for reproducibility of epidemiologic research, replication findings, pooled analyses in consortia efforts, and maximizing study value to address multiple research questions. However, barriers related confidentiality, costs, incentives often limit the extent speed data sharing. Epidemiological practices that follow Findable, Accessible, Interoperable, Reusable (FAIR) principles can these by making resources findable with necessary metadata, accessible...

10.1093/aje/kwad040 article EN public-domain American Journal of Epidemiology 2023-02-18

Obesity is associated with an increased risk of fatal prostate cancer. We aimed to elucidate the importance and relevant timing obesity weight change for cancer progression. identified 5,158 men diagnosed localized (clinical stage T1/T2) from 1986 2012 in Health Professionals Follow‐up Study. Men were followed biochemical recurrence lethal (development distant metastasis or cancer‐specific mortality) until 2012. Cox regression estimated hazard ratios (HRs) body mass index (BMI) at age 21,...

10.1002/ijc.30803 article EN International Journal of Cancer 2017-05-24

Cytotoxic chemotherapy remains the main systemic therapy for gastro-oesophageal adenocarcinoma, but resistance to is common, resulting in ineffective and often toxic treatment patients. Predictive biomarkers response would increase probability of successful therapy, none are currently recommended clinical use. We used global gene expression profiling tumour biopsies identify novel predictive cytotoxic chemotherapy. Tumour from patients (n=14) with TNM stage IB–IV adenocarcinomas receiving...

10.1038/bjc.2014.45 article EN cc-by-nc-sa British Journal of Cancer 2014-02-25
Coming Soon ...